REG - LungLife AI, INC - Block Listing Six Monthly Return

LungLife AIAnnouncement

15/05/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230515:nRSO2867Za&default-theme=true

RNS Number : 2867Z  LungLife AI, INC  15 May 2023

LungLife AI, Inc.

("LungLife" or the "Company")

 

Block Listing Six Monthly Return

 

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung
cancer, makes the following six monthly update on its block listing pursuant
to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies:

 

 Name of applicant:                                                                LungLife AI, Inc.
 Name of scheme:                                                                   1.    2010 Stock Incentive Plan

                                                                                   2.    2020 Stock Incentive Plan

                                                                                   3.    2021 Omnibus Long-Term Incentive Plan
 Number and class of securities originally admitted:                               1,356,139 common shares of US $0.0001 each
 Date of admission:                                                                15 November 2021
 Period of return:                        From:                                    15 November 2022  To:               15 May 2023
 Balance of unallotted securities under scheme(s) from previous return:            1.    475,583

                                                                                   2.    201,374

                                                                                   3.    673,990
 Plus: The amount by which the block scheme(s) has been increased since the        1.    NIL
 date of the last return (if any increase has been applied for):

                                                                                   2.    NIL

                                                                                   3.    NIL
 Less: Number of securities issued/allotted under scheme(s) during period (see     1.    NIL
 LR3.5.7G):

                                                                                   2.    NIL

                                                                                   3.    NIL
 Equals: Balance under scheme(s) not yet issued/allotted at end of period:         1.    475,583

                                                                                   2.    201,374

                                                                                   3.    673,990
 Total number of securities in issue at the end of the period                      25,485,982

 

 Name of contact:              David Anderson, Chief Financial Officer
 Telephone number of contact:  +44 (0)20 7933 8780 or lunglifeai@walbrookpr.com

 

 

 

 

 

For further information please contact:

 

 LungLife AI, Inc.                                     www.lunglifeai.com (https://www.lunglifeai.com/)
 Paul Pagano, CEO                                      Via Walbrook PR
 David Anderson, CFO

 Investec Bank plc (Nominated Adviser & Broker)        Tel: +44 (0)20 7597 5970
 Virginia Bull / Cameron MacRitchie / Lydia Zychowska

 Goodbody (Joint Broker)                               Tel: +44 (0) 20 3841 6202 / +353 (1) 667 0420
 Tom Nicholson / Stephen Kane

 Walbrook PR Limited                                    Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com
                                                       (mailto:LungLifeAI@walbrookpr.com)
 Alice Woodings / Phillip Marriage                     Mob: 07407 804 654 / 07867 984 082

 

 

About LungLife

LungLife AI is a developer of clinical diagnostic solutions designed to make a
significant impact in the early detection of lung cancer, the deadliest cancer
globally. Using a minimally invasive blood draw, the Company's LungLB® test
is designed to deliver additional information to clinicians who are evaluating
indeterminate lung nodules. For more information visit www.lunglifeai.com
(http://www.lunglifeai.com)

 

Our Purpose is to be a driving force in the early detection to lung cancer.
And our Vision is to invert the 20:80 ratio such that in years to come at
least 80% of lung cancer is detected early.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BLRGPUMWAUPWGGP